Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAF(V600) mutation-positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study-MedSci.cn

Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAF(V600) mutation-positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study

Dreno, B; Ascierto, PA; McArthur, GA; Atkinson, V; Liszkay, G; Di Giacomo, AM

JOURNAL OF CLINICAL ONCOLOGY, 2018; 36 (15):

科室
- - 订阅+
  - 更多科室
工具
服务